RNA biomarker signatures for prediction of acute kidney injury in acute coronary syndrome patients undergoing PCI

Abstract Background Acute kidney injury (AKI) represents a critical complication in patients with acute coronary syndrome (ACS), particularly in patients undergoing percutaneous coronary intervention (PCI). Current tests for detecting early AKI, such as creatinine and cystatin C, have modest sensitivity. This study explores the role of bioinformatics in creating an implementable predictive key gene in cardiorenal pathogenesis and evaluates the diagnostic potential of GTF2I, ANGPTL4, and MMP14 in predicting AKI in ACS patients. Methods This is a single-center prospective observational cohort study that enrolled 167 participants: healthy controls (n = 60), ACS patients (n = 56), and ACS patients with AKI (n = 51). Baseline clinical and renal markers were measured 24 h pre-PCI, with RNA biomarkers (GTF2I, ANGPTL4, MMP14) assessed at 48 h post-PCI, with daily creatinine monitoring performed for up to 6 days after PCI. Results GTF2I, ANGPTL4, and MMP14 were significantly elevated in ACS patients, with further increases in ACS-AKI patients. GTF2I showed the strongest predictive accuracy for AKI (AUC = 0.98), outperforming creatinine and cystatin. ANGPTL4 correlated negatively with serum creatinine (r = − 0.213, P = 0.006), suggesting a modulatory role in renal injury, while MMP14 elevations were pronounced in ACS-AKI. Notably, the combined biomarker panel achieved the highest diagnostic accuracy (AUC = 0.99), underscoring its potential as a robust early predictor of AKI. Subgroup analysis in diabetic patients revealed differential biomarker expression between AKI and non-AKI cases. Logistic regression confirmed albuminuria, ANGPTL4, GTF2I, and MMP14, in addition to several metabolic biomarkers, as significant predictors of AKI. Conclusion GTF2I, ANGPTL4, and MMP14 are promising biomarkers for predicting AKI in ACS patients and could be integrated into clinical practice for early AKI detection, improving patient management and outcomes.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2026-04-14
DOI
https://doi.org/10.1186/s12882-026-04926-w
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RNA biomarker signatures for prediction of acute kidney injury in acute coronary syndrome patients undergoing PCI

Radwa Khaled, Marwa Matboli, Sara Elsayed Abdelrahman, Emad El-Zayat et al.
BMC Nephrology
Acute Kidney Injury Research
article

RNA biomarker signatures for prediction of acute kidney injury in acute coronary syndrome patients undergoing PCI

Radwa Khaled, Marwa Matboli, Sara Elsayed Abdelrahman, Emad El-Zayat, Mohamed A. Ragheb
article en

Abstract

Abstract Background Acute kidney injury (AKI) represents a critical complication in patients with acute coronary syndrome (ACS), particularly in patients undergoing percutaneous coronary intervention (PCI). Current tests for detecting early AKI, such as creatinine and cystatin C, have modest sensitivity. This study explores the role of bioinformatics in creating an implementable predictive key gene in cardiorenal pathogenesis and evaluates the diagnostic potential of GTF2I, ANGPTL4, and MMP14 in predicting AKI in ACS patients. Methods This is a single-center prospective observational cohort study that enrolled 167 participants: healthy controls (n = 60), ACS patients (n = 56), and ACS patients with AKI (n = 51). Baseline clinical and renal markers were measured 24 h pre-PCI, with RNA biomarkers (GTF2I, ANGPTL4, MMP14) assessed at 48 h post-PCI, with daily creatinine monitoring performed for up to 6 days after PCI. Results GTF2I, ANGPTL4, and MMP14 were significantly elevated in ACS patients, with further increases in ACS-AKI patients. GTF2I showed the strongest predictive accuracy for AKI (AUC = 0.98), outperforming creatinine and cystatin. ANGPTL4 correlated negatively with serum creatinine (r = − 0.213, P = 0.006), suggesting a modulatory role in renal injury, while MMP14 elevations were pronounced in ACS-AKI. Notably, the combined biomarker panel achieved the highest diagnostic accuracy (AUC = 0.99), underscoring its potential as a robust early predictor of AKI. Subgroup analysis in diabetic patients revealed differential biomarker expression between AKI and non-AKI cases. Logistic regression confirmed albuminuria, ANGPTL4, GTF2I, and MMP14, in addition to several metabolic biomarkers, as significant predictors of AKI. Conclusion GTF2I, ANGPTL4, and MMP14 are promising biomarkers for predicting AKI in ACS patients and could be integrated into clinical practice for early AKI detection, improving patient management and outcomes.

BMC NephrologyVol. 27(1)
Ain Shams University (EG), Cairo University (EG)
Ain Shams University
Good health and well-being
Openalex Percentile: Top 24%
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.